UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Ucb SA tiene un dividendo anual de 0.79 por acción, con un rendimiento del 0.00%. El dividendo se paga anualmente y la última fecha ex-dividendo fue Apr 28, 2025.
Rendimiento de dividendos
Dividendo anual
Fecha de ex-dividendos
0.00%
$0.79
Apr 28, 2025
Frecuencia de pago
Relación de pago
Anualmente
0.00%
Historial de dividendos
Fecha de ex-dividendos
Monto en efectivo
Fecha de Registro
Fecha de Pago
Apr 28, 2025
$0.7904
Apr 28, 2025
May 14, 2025
Apr 26, 2024
$0.728
Apr 29, 2024
May 15, 2024
May 1, 2023
$0.732
May 2, 2023
May 18, 2023
Apr 29, 2022
$0.6845
May 2, 2022
May 18, 2022
May 7, 2021
$0.7626
May 10, 2021
May 19, 2021
May 4, 2020
$0.6691
May 5, 2020
May 21, 2020
Gráficos de dividendos
UCBJY Dividendos
UCBJY Crecimiento de Dividendos (YoY)
Follow-Up Questions
¿Cuál es el dividendo actual pagado por Ucb SA y su dividendo anual?
¿Cuál es el ratio de pago de dividendos de Ucb SA?